...
fbiop-img

Fortress Biotech Inc Pref Series A, Preferred Stock

FBIOP

NAQ

$6.75

+$0.38

(5.97%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$34.19M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
15.82K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
45.96%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.75
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.86 L
$17.47 H
$6.75

About Fortress Biotech Inc Pref Series A, Preferred Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameFBIOPSectorS&P500
1-Week Return-3.71%-3.35%-2.97%
1-Month Return30.59%-3.49%-0.66%
3-Month Return20.43%-12.6%2.71%
6-Month Return-57.73%-6.91%7.21%
1-Year Return-42.4%1.19%23.04%
3-Year Return-74.34%-0.21%28.43%
5-Year Return-66.96%33.09%82.88%
10-Year Return-72.16%93.55%184.63%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue36.63M45.60M68.79M75.74M84.51M[{"date":"2019-12-31","value":43.34,"profit":true},{"date":"2020-12-31","value":53.96,"profit":true},{"date":"2021-12-31","value":81.4,"profit":true},{"date":"2022-12-31","value":89.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue10.53M14.59M32.08M30.77M26.66M[{"date":"2019-12-31","value":32.83,"profit":true},{"date":"2020-12-31","value":45.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.92,"profit":true},{"date":"2023-12-31","value":83.09,"profit":true}]
Gross Profit26.10M31.00M36.71M44.97M57.85M[{"date":"2019-12-31","value":45.11,"profit":true},{"date":"2020-12-31","value":53.59,"profit":true},{"date":"2021-12-31","value":63.45,"profit":true},{"date":"2022-12-31","value":77.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin71.25%67.99%53.36%59.37%68.45%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.44,"profit":true},{"date":"2021-12-31","value":74.89,"profit":true},{"date":"2022-12-31","value":83.33,"profit":true},{"date":"2023-12-31","value":96.08,"profit":true}]
Operating Expenses136.92M125.28M215.71M247.23M200.19M[{"date":"2019-12-31","value":55.38,"profit":true},{"date":"2020-12-31","value":50.67,"profit":true},{"date":"2021-12-31","value":87.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.98,"profit":true}]
Operating Income(110.82M)(94.27M)(179.00M)(202.26M)(142.34M)[{"date":"2019-12-31","value":-11081900000,"profit":false},{"date":"2020-12-31","value":-9427000000,"profit":false},{"date":"2021-12-31","value":-17900100000,"profit":false},{"date":"2022-12-31","value":-20226000000,"profit":false},{"date":"2023-12-31","value":-14234200000,"profit":false}]
Total Non-Operating Income/Expense(131.00K)(22.39M)9.53M(22.14M)(26.31M)[{"date":"2019-12-31","value":-1.37,"profit":false},{"date":"2020-12-31","value":-234.94,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-232.39,"profit":false},{"date":"2023-12-31","value":-276.09,"profit":false}]
Pre-Tax Income(101.66M)(102.85M)(164.35M)(213.46M)(153.63M)[{"date":"2019-12-31","value":-10166000000,"profit":false},{"date":"2020-12-31","value":-10284900000,"profit":false},{"date":"2021-12-31","value":-16435300000,"profit":false},{"date":"2022-12-31","value":-21346400000,"profit":false},{"date":"2023-12-31","value":-15363300000,"profit":false}]
Income Taxes(49.85M)136.00K473.00K449.00K521.00K[{"date":"2019-12-31","value":-9568.33,"profit":false},{"date":"2020-12-31","value":26.1,"profit":true},{"date":"2021-12-31","value":90.79,"profit":true},{"date":"2022-12-31","value":86.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(51.81M)(102.98M)(164.83M)(213.91M)(154.15M)[{"date":"2019-12-31","value":-5180900000,"profit":false},{"date":"2020-12-31","value":-10298500000,"profit":false},{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-15415400000,"profit":false}]
Income From Continuous Operations(101.66M)(102.98M)(164.83M)(213.91M)(182.62M)[{"date":"2019-12-31","value":-10166000000,"profit":false},{"date":"2020-12-31","value":-10298500000,"profit":false},{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-18261500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(51.81M)(102.98M)(164.83M)(213.91M)(60.64M)[{"date":"2019-12-31","value":-5180900000,"profit":false},{"date":"2020-12-31","value":-10298500000,"profit":false},{"date":"2021-12-31","value":-16482600000,"profit":false},{"date":"2022-12-31","value":-21391300000,"profit":false},{"date":"2023-12-31","value":-6063700000,"profit":false}]
EPS (Diluted)(0.71)(0.56)---[{"date":"2019-12-31","value":-71,"profit":false},{"date":"2020-12-31","value":-55.54,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

FBIOP
Cash Ratio 0.84
Current Ratio 1.23
Quick Ratio 1.06

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FBIOP
ROA (LTM) -36.41%
ROE (LTM) -1739.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FBIOP
Debt Ratio Lower is generally better. Negative is bad. 1.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.17

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FBIOP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.41
P/B 0.00
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Fortress Biotech Inc Pref Series A share price today?

Fortress Biotech Inc Pref Series A (FBIOP) share price today is $6.75

Can Indians buy Fortress Biotech Inc Pref Series A shares?

Yes, Indians can buy shares of Fortress Biotech Inc Pref Series A (FBIOP) on Vested. To buy Fortress Biotech Inc Pref Series A from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FBIOP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Fortress Biotech Inc Pref Series A be purchased?

Yes, you can purchase fractional shares of Fortress Biotech Inc Pref Series A (FBIOP) via the Vested app. You can start investing in Fortress Biotech Inc Pref Series A (FBIOP) with a minimum investment of $1.

How to invest in Fortress Biotech Inc Pref Series A shares from India?

You can invest in shares of Fortress Biotech Inc Pref Series A (FBIOP) via Vested in three simple steps:

  • Click on Sign Up or Invest in FBIOP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Fortress Biotech Inc Pref Series A shares
What is Fortress Biotech Inc Pref Series A 52-week high and low stock price?

The 52-week high price of Fortress Biotech Inc Pref Series A (FBIOP) is $17.47. The 52-week low price of Fortress Biotech Inc Pref Series A (FBIOP) is $4.86.

What is Fortress Biotech Inc Pref Series A price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Fortress Biotech Inc Pref Series A (FBIOP) is

What is Fortress Biotech Inc Pref Series A price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Fortress Biotech Inc Pref Series A (FBIOP) is 0.00

What is Fortress Biotech Inc Pref Series A dividend yield?

The dividend yield of Fortress Biotech Inc Pref Series A (FBIOP) is 45.96%

What is the Market Cap of Fortress Biotech Inc Pref Series A?

The market capitalization of Fortress Biotech Inc Pref Series A (FBIOP) is $34.19M

What is Fortress Biotech Inc Pref Series A’s stock symbol?

The stock symbol (or ticker) of Fortress Biotech Inc Pref Series A is FBIOP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top